openPR Logo
Press release

Human Albumin and Factor Vlll Market to Register Substantial Expansion by 2023

10-17-2017 07:59 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Human Albumin and Factor Vlll Market to Register Substantial

Human albumin is a type of protein, commonly found in human blood plasma. Human albumin is normally synthesized in liver. Factor Vlll is a blood clotting protein and also known as anti-hemophilic factor (AHF). Defect in production of Factor Vlll may result in hemophilia A (genetic deficiency in clotting factor). This protein circulates in bloodstream in an inactive form. In response to the injury, factor Vlll initiates the chemical reaction that forms a blood clot. Factor Vlll are also extracted from the human plasma or engineered from mammalian cell culture by means of recombinant DNA technology and can be used to treat patients with hemophilia disease.

Request Sample Copy of the Report@

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10238 

 

Rising incidences of hemophilia will drive the growth of the market of human albumin and factor VIII market. According to National Hemophilia Foundation, approximately one in 5,000 male in the U.S. are affected with hemophilia. In addition, strategic collaboration by key players in order to introduce novel treatment options will further drive the market growth. For example, Novo Nordisk collaborated with National Hemophilia Foundation aiming to develop novel treatment option for hemophilia disease. Thus, these types of collaboration will build healthy platform to attract new customers and hence drive the market growth. Furthermore, rising geriatric population will significantly drive the market growth of human albumin and factor VIII market. According to a report published by World Health Organization (WHO), the number of people aged 65 years and above is expected to increase from 605 million to 2 billion by 2050. Additionally, advances in factor VIII product resulted in a major increase in quality of life of patients and hence supports the growth of human albumin and factor VIII. Moreover, various other factors like rising number of people with bleeding disorders, rising use of albumin as cell culture medium ingredient and low cost therapy will further augment the growth of the market. However, stringent regulation and lack of adequate plasma supplies will restrain the growth of human albumin and factor VIII market. In addition, high cost of therapies coupled with lack of adequate treatment modalities in developing countries like Asia-Pacific will restrain the growth of this market. For example, advanced therapeutics for the treatment are only available in the developed countries like North America and Europe.

Geographically, North America dominates the global human albumin and factor VIII market. Increasing use of plasma derived products in North America will drive the growth of human albumin and factor VIII market in North America. Europe is considered as the second largest market of human albumin and factor VIII market. The growth of the market in Europe is majorly driven by aging population. Rise in geriatric population will increase the risk of the people diagnosed with hemophilia which drives the growth of human albumin and factor VIII market in European market. According to Eurostat (European Commission) report published in 2013, around 17.8% of the European population were aged 65 years and above. The market of human albumin and factor VIII market in Asia-Pacific holds a strong growth as there is a rise in total number of bleeding disorder cases in this region. In addition, emerging countries like India and China are increasingly importing albumins from western countries (i.e. North America and Europe) which will ultimately drive the overall growth of this market in Asia-Pacific region.

Request TOC of the Report@

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=10238

 

Some of the key players dominating the global human albumin and factor VIII market comprises Baxter International, Inc., Talecris Plasma Resources, Grifols, S.A., Novo Nordisk, CSL Limited and others.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Human Albumin and Factor Vlll Market to Register Substantial Expansion by 2023 here

News-ID: 776011 • Views:

More Releases from Transparency Market Research

Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn
Digital Health Market Estimated at US$ 1.1 Trillion by 2031, TMR Study
Digital Health Market Estimated at US$ 1.1 Trillion by 2031, TMR Study
In 2022, the worldwide 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 garnered a valuation of US$ 382.5 billion. Projections indicate a steady growth trajectory, with a compound annual growth rate (CAGR) of 13.1% anticipated from 2023 to 2031, ultimately culminating in a total valuation of US$ 1.1 trillion by the conclusion of 2031. Market analysts foresee a promising outlook characterized by the burgeoning prevalence of chronic diseases and the increasing adoption of smartphones and internet

All 5 Releases


More Releases for VIII

Recombinant Factor VIII Market: Strong Development till 2030
Prophecy Market Insights has recently published the Recombinant Factor VIII informational report which will help retailers, manufacturers, and distributors to understand and realize the market drivers, restraints, and opportunities to generate revenue, and trends that are instrumental in shaping the target market and its revenue. This Recombinant Factor VIII market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry. The report
Global Recombinant Factor VIII Market Research Report
This report studies the global Recombinant Factor VIII market status and forecast, categorizes the global Recombinant Factor VIII market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Shire (Baxter) Bayer CSL Pfizer Biogen Octapharma NovoNordisk Geographically, this report studies the top producers
Global Plasma-derived Factor VIII Market Research Report
This report studies the global Plasma-derived Factor VIII market status and forecast, categorizes the global Plasma-derived Factor VIII market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Shire (Baxter) Octapharma CSL Grifols Greencross Kedrion BPL Hualan Bio RAAS Geographically, this report studies
Human Coagulation Factor VIII Market 2018 Forecast to 2023
Scope of the Report: This report focuses on the Human Coagulation Factor VIII in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Sample Copy of This Report: https://marketreportscenter.com/request-sample/590851 Market Segment by Manufacturers, this report covers Shire (Baxter) Bayer CSL Pfizer Grifols Biogen Octapharma NovoNordisk Greencross Kedrion BPL Hualan Bio RAAS Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia
United States Human Coagulation Factor VIII Market Report 2016
MarketResearchReports.biz has recently announced the addition of a market study “ United States Human Coagulation Factor VIII Market Report 2016 ”, is a comparative analysis of the global market. Notes: Sales, means the sales volume of Human Coagulation Factor VIII Revenue, means the sales value of Human Coagulation Factor VIII This report studies sales (consumption) of Human Coagulation Factor VIII in United States market, focuses on the top players, with sales, price, revenue
Factor VIII Industry: Market Research to 2020
“Global Factor VIII Sales Market Report 2016” Order This Report by calling BigMarketResearch.com at +1-971-202-1575. This report studies sales (consumption) of Factor VIII in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering CSL Ltd. (Australia) Grifols S.A (Spain) Baxalta Incorporated (U.S.) Octapharma AG (Switzerland) Kedrion S.p.A (Italy) China Biologic Products, Inc. (China) Biotest